Proceeds Purposes The Series A capital will support the company’s lead sphingosine-1-phosphate receptor 1 (S1P1) clinical candidate through Phase 1 human clinical trials, development of a second IND candidate, as well as the select partnering of the proprietary technology platform for GPCR drug discovery and development.